

## TNF- $\alpha$

1

<sup>1</sup>, <sup>2</sup>, <sup>3</sup>

오지민<sup>1</sup> · 고은미<sup>1</sup> · 김형진<sup>1</sup> · 이재준<sup>1</sup> · 안중경<sup>1</sup> · 차훈석<sup>1</sup> · 이주홍<sup>2</sup> · 장기택<sup>3</sup>

= Abstract =

### Exacerbation of Psoriatic Skin Lesion followed by TNF- $\alpha$ Antagonist Treatment

Ji-Min Oh<sup>1</sup>, Eun-Mi Koh<sup>1</sup>, Hyungjin Kim<sup>1</sup>, Jaejoon Lee<sup>1</sup>, Joong Kyong Ahn<sup>1</sup>,  
Hoon-Suk Cha<sup>1</sup>, Joo Heung Lee<sup>2</sup>, Kee Taek Jang<sup>3</sup>

*Divisions of Rheumatology<sup>1</sup>, Dermatology<sup>2</sup>, and Pathology<sup>3</sup>, Sungkyunkwan University  
School of Medicine, Samsung Medical Center, Seoul, Korea*

TNF- $\alpha$  antagonists have been successfully utilized in the treatment of autoimmune diseases, including psoriasis and psoriatic arthritis. Paradoxically, new onset or exacerbation of psoriatic lesions during treatment with TNF- $\alpha$  antagonists have been reported. It has been postulated that TNF- $\alpha$  blockade may cause disruption in the balance between TNF- $\alpha$  and type 1 interferon (IFN)- $\alpha$ , which are the key players in the pathogenesis of psoriasis. We report a case of psoriasis exacerbation during TNF- $\alpha$  antagonist therapy in a 53-years-old man with ankylosing spondylitis. The patient has been treated with etanercept for 3 years and 7 months when he developed accelerated deterioration of psoriasis. His condition was previously under control solely by local treatment. Physical examination revealed vigorous desquamative lesions with silvery scale in both lower legs. Deterioration of psoriasis was attributed to etanercept therapy and was subsequently discontinued. Clinical improvement of psoriasis has been observed 2 months following cessation of etanercept.

**Key Words:** Psoriasis, TNF- $\alpha$  antagonists, Ankylosing spondylitis

<접수일 : 2009년 10월 7일, 수정일 : 2010년 1월 6일, 심사통과일 : 2010년 1월 7일>

※통신저자 : 고 은 미

서울시 강남구 일원동

삼성의료원 류마티스내과

Tel : 02) 3410-3433, Fax : 02) 3410-3849, E-mail : emkoh@skku.edu

## 서 론

Tumor necrosis factor (TNF)- $\alpha$  , Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 9.84 etanercept . etanercept 1 5 , etanercept etanercept 8 (1) TNF- $\alpha$  1 7 (2). 2 2008 golimumab 16 etanercept . BASDAI 9.63 etaner- 1 (3). TNF- cept 0.99  $\alpha$  TNF- 5 2008 5  $\alpha$  TNF- $\alpha$  etanercept . Etanercept (interferon- $\alpha$ ) 6 (4). 신체검사 소견: , , , TNF- $\alpha$  , 1 1 30 증 례 BASDAI

환 자: 53

주 소:

현병력: etanercept 3 7

( 1).

과거력: 26

, sulfasalazine,

, ,

. 9

, ,

D,

. 7

6

3 7

4


10



**Fig. 1.** Widespread desquamative lesions with scales following etanercept therapy (A) right lower leg, (B) right knee.



**Fig. 2.** Lumbar spine - sacrum X-ray Bony ankylosis is noted in both sacroiliac joints and bamboo spine is observed.



**Fig. 3.** Pathologic finding from right knee. Acanthosis of the basal layer, and spongiosis and supracorneal pustules are shown (Original magnification  $\times 100$ , Hematoxylin and Eosin staining).

2.58  
0 cm (chest expansion)  
0 cm  
검사실 소견: Etanercept 3 7  
14,640/uL, 10.2 g/dL,  
399,000/uL, C- 6.59 mg/dL (  
0~0.3), 120 mm/hr ( 0  
~22), 7.5 g/dL, 3.3 g/dL,  
78.2 mg/dL, 1.57 mg/dL,  
9.3 mg/dL, 3.6 mg/dL

고 찰

TNF- $\alpha$  , , ,  
TNF- $\alpha$  , , ,  
(5). TNF- $\alpha$  ,  
TNF- $\alpha$   
TNF- $\alpha$

2).  
(spongiosis of basal layer)  
(acanthosis) (granular layer) melanoma  
supracorneal pustules (6).  
( 3). TNF- $\alpha$

치료 및 경과: Etanercept  
etanercept TNF- $\alpha$   
D , , 9,826  
25  
etanercept infliximab adali-

mumab  
(2). adalimumab etanercept infliximab  
mab

TNF- $\alpha$

etanercept human (13). TNF- $\alpha$ , T

class effect (7). , (12).  
TNF- $\alpha$

104 TNF- $\alpha$

50% , 22% 5%  
, 16% , D

Infliximab 53%, etanercept ,  
29% adalimumab TNF- $\alpha$   
18% (8). 2009 8  
TNF- $\alpha$  5% TNF- $\alpha$   
, acitretin, methotrexate,  
9 cyclosporine TNF- $\alpha$   
etanercept TNF- $\alpha$   
1 5 TNF- $\alpha$   
3 4 (8).  
20%  
TNF- $\alpha$   
TNF- $\alpha$   
TNF- $\alpha$   
(14). TNF- $\alpha$   
, ,  
(streptococcus),  
(9).  
TNF- $\alpha$   
(paradoxical response)  
IFN- $\alpha$   
plasmacytoid TNF- $\alpha$   
IFN- $\alpha$  요 약  
(4).  
(10) TNF- $\alpha$   
(11,12).

TNF- $\alpha$ TNF- $\alpha$ TNF- $\alpha$ 

plasmacytoid

interferon- $\alpha$ TNF- $\alpha$ 

1

## 참고문헌

- 1) Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, et al. Guideline for anti-TNF- $\alpha$  therapy in psoriatic arthritis. *Rheumatology (Oxford)* 2005;44:390-7.
- 2) Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor  $\alpha$  therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2009;68:209-15.
- 3) Choi YJ, Kim DS, Park JM, Oh SH, Park YK, Lee JH. A case of psoriasiform eruption triggered by tumor necrosis factor- $\alpha$  antagonist therapy. *Korean J Dermatol* 2008;46:721-3.
- 4) Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN- $\alpha$  in autoimmune diseases. *Proc Natl Acad Sci USA* 2005;102:3372-7.
- 5) Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2004;18:59-80.
- 6) Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor adverse events exposure-adjusted pooled analyses of serious treatments in rheumatoid arthritis. *Ann Rheum Dis* 2009; 68;1136-45.
- 7) Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor- $\alpha$ -induced psoriasis. *J Rheumatol* 2006;33:1411-4.
- 8) Angelique NC, Karen TG, Jeffery SH, Daniel FB. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. *Arthritis Rheum* 2008;59:996-1001.
- 9) Rashmi R, Rao KS, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. *Clin Exp Dermatol* 2009;34:658-63.
- 10) Sfrikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. *Arthritis Rheum* 2005;52:2513-8.
- 11) Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor  $\alpha$  antagonists. *Ann Rheum Dis* 2006;65:405-7.
- 12) Jean DC, Irina B, Valerie B, Agnes P, Xavier C, Mrtine B, et al. Psoriasis induced by tumor necrosis factor- $\alpha$  antagonist therapy: a case series. *J Rheumatol* 2007;34:380-5.
- 13) Spyros A, Athina P, Stella D, Areti T. Tumor necrosis factor- $\alpha$  antagonist-induced psoriasis: yet another paradox in medicine. *Clin Rheumatol* 2008;27:377-80.
- 14) Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, et al. Onset or exacerbation of cutaneous psoriasis during TNF $\alpha$  antagonist therapy. *Joint Bone Spine* 2008;75:315-8.
- 15) Uwe W, Gesina H, André K, Jaqueline S, Erich K, Gunter H. Tumor necrosis factor- $\alpha$  inhibitor-induced psoriasis or psoriasiform exanthemata. *Am J Clin Dermatol* 2008;9:1-14.